Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal Cancer

Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal Cancer is a phase 2, interventional study registered as NCT07068763 by Sir Run Run Shaw Hospital, with a registry enrolment figure of 52 participants, started 2025-10-09 and due to reach its primary completion in 2026-12-31. Interventions recorded: Lymph-node-sparing short-course radiotherapy; Capecitabine; PD-1/CTLA-4 inhibitor (Aiparolitoworixureli injection). Conditions listed: Rectal Cancer. Primary outcome: Clinical and pathological complete response rate (CR rate). Colorectal eligibility wording from the registry: "Patients diagnosed with low rectal cancer within 7 cm from the lower edge of the tumor to the anal verge by pelvic MRI and rectal ultrasound, the clinical stage is cT2-3N0M0". Sites: China. No results are recorded here; the registry entry is the source.